Scarica l'app Stockscreener
0.5457
5.68%
-0.0329
Dopo l'orario di chiusura:
.54
-0.0057
-1.04%
AIM ImmunoTech Inc Borsa (AIM) Ultime notizie
AIM ImmunoTech Inc. Reports Audit Findings with Going Concern Emphasis and Positive Clinical Trial Progress for Ampligen in Pancreatic Cancer Treatment - Quiver Quantitative
AIM ImmunoTech Provides Routine Update on Annual Filings - The Manila Times
Aim Immunotech Provides Routine Update On Annual Filings - TradingView — Track All Markets
AIM ImmunoTech Inc. 8-K Filing Details Equity Distribution Agreement Amendment and NYSE American Listing - Minichart
AIM ImmunoTech Expands At-The-Market Equity Offering Capacity - TipRanks
AIM ImmunoTech's ATM Expansion Hides Ongoing Liquidity Stress and Shareholder Squeeze Risk - Bitget
AIM ImmunoTech amends equity distribution agreement to remove share sale limit - Investing.com
AIM ImmunoTech Expands ATM Equity Program With Maxim, Removing Prior $3 Million Cap - TradingView — Track All Markets
AIM ImmunoTech (NYSE: AIM) lifts cap on at-the-market stock sales - Stock Titan
AIM ImmunoTech (NYSE American: AIM) ups ATM capacity to $3.41M under S‑3 - Stock Titan
Constellation Brands To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
AIM Stock Target Price Lowered by Ascendiant Capital | AIM Stock News - GuruFocus
AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event - ChartMill
AIM SEC FilingsAim Immunotech 10-K, 10-Q, 8-K Forms - Stock Titan
AIM ImmunoTech Inc (AIM) Stock Price, Trades & News - GuruFocus
AIM ImmunoTech Inc. (AIM) Stock Price, News, Quote & History - Yahoo! Finance Canada
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
Is AIM ImmunoTech (AIM) stock outpacing its medical peers this year? - MSN
AIM PE Ratio & Valuation, Is AIM Overvalued - Intellectia AI
AIM ImmunoTech 2025 Annual Report: Focus on Ampligen for Pancreatic Cancer, Clinical Trials, and R&D Highlights - Minichart
AIM ImmunoTech 10-K: $0.09M Revenue, $(8.62) EPS, $13.96M Net Loss - TradingView — Track All Markets
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Going concern risk and oncology plans at AIM ImmunoTech (AIM) detailed - Stock Titan
What's going on with AIM ImmunoTech stock Friday? - msn.com
AIM ImmunoTech Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Earnings Scheduled For March 24, 2026 - Sahm
Thermo Fisher Scientific (TMO) Partners With AIM ImmunoTech on Phase 3 Cancer Trial - Insider Monkey
If You Invested $1,000 in Aim Immunotech (AIM) - Stock Titan
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
Why did AIM stock more than double in pre-market today? - msn.com
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Sahm
AIM ImmunoTech Stock Today: AIM Surges 44% on Massive Volume After Patent Approval and Cancer Trial Progress - International Business Times
Alibaba Posts Downbeat Earnings, Joins Guardian Pharmacy, Micron And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionAIM ImmunoTech (AMEX:AIM), Almonty Indus (NASDAQ:ALM) - Benzinga
AIM ImmunoTech Inc. (AIM) Latest Stock News & Headlines - Yahoo Finance
AIM ImmunoTech Gains Japanese Patent Approval for Cancer Treatme - GuruFocus
Why Five Below Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
AIM ImmunoTech (AIM) Stock Soars Nearly 100% on Japanese Cancer Treatment Patent Approval - MEXC
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
AIM ImmunoTech (AIM) Stock Jumps 97% After Japan Patent Approval for Cancer Treatment - MEXC
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
Why Is AIM ImmunoTech Stock Gaining Today? - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer - GlobeNewswire
AIM ImmunoTech Expands Cancer Drug Trials with Key Collaboration - StocksToTrade
AIM ImmunoTech Engages Thermo Fisher’s PPD for Phase 3 Cancer Trial - timothysykes.com
Patent Approval Drives Stock Price Surge: AIM ImmunoTech Inc. (AIM) shares soared 88% in pre-market trading today, reaching $1.34 - Bitget
Why Is AIM ImmunoTech Stock (AIM) Up Today? - TipRanks
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors - Bitget
Why Did AIM Stock More Than Double In Pre-Market Today? - Asianet Newsable
Patent Implementation and Core Therapy: AIM ImmunoTech Inc. announces that its innovative cancer therapy patent combining Ampligen with immune checkpoint inhibitors has received final approval in Japan - Bitget
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):